Australian Journal of General Practice最新文献

Background and objectives: Surgical site infection (SSI) after dermatological surgery is associated with poor outcomes. Developing clinical prediction rules based on the predicted probability of infection might encourage guided prophylaxis and judicious prescribing. The purpose of this study was to develop a clinical prediction rule based on identified risk factors for SSI in a large general practice patient cohort.

Method: We examined a large, pooled dataset from four randomised controlled trials performed in a regional centre of North Queensland, Australia. Multivariable logistic regression identified a prediction model. Bootstrapping was used for internal validation. A scoring system was based on predicted probabilities of infection.

Results: The final prediction rule included age >55 years and the anatomical site, histology and complexity of the excision. The area under the curve was 0.704.

Discussion: Our prediction rule encourages judicious use of prophylaxis in clinical practice.

Background and objectives: Previous research identified numerous barriers to general practitioner (GP) use of cardiovascular disease (CVD) risk guidelines, and it is unclear whether these issues have been resolved. This study explored recent GP experiences.

Method: Interviews with 18 GPs in an Australian state with relatively few COVID-19 cases in 2021 were transcribed and coded using a framework analysis approach, with data mapped to five previously identified CVD risk assessment strategies: absolute risk focused, absolute risk adjusted, clinical judgement, passive disregard and active disregard.

Results: GPs used various CVD risk calculators to inform clinical decision making, but there were concerns about accuracy, the role of extra risk factors and less 'personalised' assessment. GPs addressed these concerns by requesting additional tests, subjectively adjusting the CVD risk assessment to account for extra risk factors and focusing on individual risk factors.

Discussion: Many barriers to CVD risk assessment guidelines remain. GP support is needed to implement revised guidelines.

Background: Reducing weight stigma in healthcare is critical to supporting and improving the health of people living with overweight or obesity and decreasing the risk of adverse patient outcomes. We were invited as stigma researchers to participate in an online workshop alongside community members, healthcare professionals and policymakers to codesign guidance for reducing weight stigma in healthcare. This workshop prompted us to reflect on why and how weight stigma should be addressed in healthcare, and to provide recommendations for healthcare professionals and policymakers to reduce weight stigma in healthcare.

Objective: This paper presents our reflections and recommendations for addressing weight stigma in healthcare following the codesign workshop.

Discussion: Recommendations include targeting individual healthcare professionals and involving clear, practical guidelines and training that leverage the notions of 'do no harm', improving practice and recognising biases. Importantly, such strategies must be couched in broader structural approaches to weight stigma reduction.

Background: Following major achievements seen with drug therapies for the treatment of advanced melanoma in the last decade, they now also have an ever-increasing role for the treatment of earlier stage disease. This review outlines the current drugs used to treat melanoma, and how general practitioners (GPs) can assist in the management of patients with melanoma and the associated toxicities with treatment.

Objective: This review summarises the evolving status of melanoma care, emphasising when to refer patients to medical oncologists as part of the multidisciplinary team. It provides guidance into recognising and managing immune-related adverse events (irAEs) associated with immunotherapy, and provides insights into the future changes in clinical practice.

Discussion: Drug therapies are increasingly used for the treatment of many patients with melanoma. Early referral is crucial, and clinical trials remain the best choice for most patients. Recognition and prompt management of irAEs is vital, and collaboration between GPs and oncologists is essential for best care.

Background and objectives: Transition from hospital to community care is well established as a high-risk time for patients. Inadequate clinical handover to general practice puts patients at risk of medical error, adverse events and rehospitalisation. We sought to understand the effects on general practitioners (GPs) of poor clinical handover from the inpatient, outpatient and emergency department settings.

Method: Qualitative methodology was used through conducting semi-structured interviews with purposively selected GPs. Interviews were undertaken until data reached saturation and no new themes emerged. The interviews were thematically analysed and coded.

Results: Key themes emerging included poor communication leading to patient safety concerns, time taken away from patient care and GPs experiencing a lack of professional respect.

Discussion: Clinical handover from the hospital sector remains a source of frustration for GPs. Poor handover demonstrates a lack of appreciation for the important role of the GP in continuing the care of patients and puts patients at risk of poor outcomes.

Background: Australian general practice patients commonly have significant solar damage. This can lead to the manifestation of actinic keratoses (AKs) as discreet lesions or as field disease, with these lesions potentially giving rise to keratinocyte cancers (KCs). Therefore, a pragmatic approach is needed to assess and manage these higher-risk patients.

Objective: This article discusses an approach to managing patients with significant solar damage from a primary care perspective, focusing on the assessment and treatment of AKs as individual lesions and within a field.

Discussion: Significant solar damage is typified by the presence of AKs, commonly seen as field disease. Several field treatment modalities are available for patients. Treatment options need to be tailored to the individual patient and site of disease to maximise adherence and efficacy.